Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of ...

A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...

GSK on Monday also announced a $1 billion deal to acquire another privately held cancer drug developer, IDRx. The agreement ...

GSK said the acquisition of IDRx will help it target a “major gap in the current standard of care” related to ...

This comes after GSK made several agreements in 2024, including a deal with cancer biotech firm IDRx, Inc., worth up to $1.15 billion, which was announced on Monday. The acquisition of IDRx is aimed ...